Because the haemolytic risk of PQ-based regimens in malaria-endemic regions depends also on the severity of G6PD mutations involved in the deficiency, G6PD genetic testing could be useful when the benefits of PQ treatment outweigh the risk in patients living in these areas. This evidence concerns the gene G6PD and malaria.